Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Compare the effects of ursodiol (ursodeoxycholic acid), with and without methotrexate, on pruritus, incapacitation index, and serum markers of activity and severity in patients with primary biliary cirrhosis.

II. Compare the effects of these regimens on the development of ascites, encephalopathy, varices (or bleeding from pre-existing varices), histologic liver changes, transplantation, and survival.

III. Compare the toxicity and safety of each regimen.


Clinical Trial Description

PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution and Ludwig histologic stage.

All patients are treated with ursodiol (ursodeoxycholic acid, UDCA) for 6 months. If entry criteria continue to be met, patients are randomly assigned to UDCA/methotrexate or UDCA/placebo.

Combination therapy continues for at least 5 years. ;


Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00004784
Study type Interventional
Source Office of Rare Diseases (ORD)
Contact
Status Completed
Phase Phase 3
Start date January 1994

See also
  Status Clinical Trial Phase
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Terminated NCT00550862 - Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) Phase 2
Completed NCT00004748 - Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Phase 3
Completed NCT03630718 - Trial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With PBC in Women N/A
Completed NCT00004842 - Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Phase 1
Terminated NCT03633227 - Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Phase 4
Terminated NCT00125281 - SAMe to Treat Biliary Cirrhosis Symptoms Phase 2
Completed NCT04629456 - Physical Therapy for Liver Cirrhosis N/A
Completed NCT03468699 - Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia Phase 2
Completed NCT00006168 - Ursodiol-Methotrexate for Primary Biliary Cirrhosis Phase 3
Completed NCT00570765 - Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) Phase 2
Recruiting NCT00160940 - Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis N/A
Recruiting NCT03146910 - Swiss Primary Biliary Cholangitis Cohort Study
Terminated NCT03265249 - BRIDGE Device for Post-operative Pain Control N/A
Terminated NCT02308111 - Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Phase 4
Recruiting NCT02936596 - Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome N/A
Completed NCT00406237 - Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis Phase 1
Completed NCT04047160 - Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) Phase 1
Recruiting NCT00145964 - Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC) N/A
Terminated NCT03476993 - Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis Phase 2